CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+18.02%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.06B
AUM Growth
+$1.06B
(-1.1%)
Cap. Flow
-$150M
Cap. Flow
% of AUM
-14.08%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
501
New
15
Increased
263
Reduced
171
Closed
24
Top Buys
| 1 |
SPDR Gold Trust
GLD
|
$6.59M |
| 2 |
iShares Gold Trust Micro
IAUM
|
$4.62M |
| 3 |
Intuit
INTU
|
$3.73M |
| 4 |
SPDR Gold MiniShares Trust
GLDM
|
$3.6M |
| 5 |
T-Mobile US
TMUS
|
$2.35M |
Top Sells
| 1 |
Apple
AAPL
|
$17.4M |
| 2 |
NVIDIA
NVDA
|
$12.2M |
| 3 |
Microsoft
MSFT
|
$11.5M |
| 4 |
Amazon
AMZN
|
$8.86M |
| 5 |
Broadcom
AVGO
|
$8.43M |
Sector Composition
| 1 | Technology | 38.15% |
| 2 | Healthcare | 22.68% |
| 3 | Communication Services | 12.64% |
| 4 | Consumer Discretionary | 11.62% |
| 5 | Consumer Staples | 3.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ORKA
376
Oruka Therapeutics, Inc. Common Stock
ORKA
$583M
| $84.3K | 0.01% |
7,520
+11
| +0.1% | +$123 |
|
377
Precigen
PGEN
$1.42B
| $84.2K | 0.01% |
59,286
+542
| +0.9% | +$770 |
|
|
RAPP
378
Rapport Therapeutics
RAPP
$597M
| $83.3K | 0.01% |
7,330
-7
| -0.1% | -$80 |
|
379
Galapagos
GLPG
$2.05B
| $83.3K | 0.01% |
2,976
+45
| +2% | +$1.26K |
|
380
Regenxbio
RGNX
$461M
| $82.7K | 0.01% |
10,075
+137
| +1% | +$1.13K |
|
381
Tourmaline Bio
TRML
$606M
| $82.5K | 0.01% |
5,159
+16
| +0.3% | +$256 |
|
382
Kanzhun
BZ
$10.9B
| $82.1K | 0.01% |
4,600
-60,000
| -93% | -$1.07M |
|
383
Savara
SVRA
$572M
| $79.1K | 0.01% |
34,714
+290
| +0.8% | +$661 |
|
384
Aura Biosciences
AURA
$392M
| $78K | 0.01% |
12,453
+2,434
| +24% | +$15.2K |
|
385
Pacific Biosciences
PACB
$384M
| $77.1K | 0.01% |
62,190
+5,339
| +9% | +$6.62K |
|
386
iTeos Therapeutics
ITOS
| $76.6K | 0.01% |
7,687
+359
| +5% | +$3.58K |
|
387
Solid Biosciences
SLDB
$423M
| $75.8K | 0.01% |
15,569
+261
| +2% | +$1.27K |
|
388
Pulse Biosciences
PLSE
$1.02B
| $75.5K | 0.01% |
5,000
-8,551
| -63% | -$129K |
|
|
TECX
389
Tectonic Therapeutic, Inc. Common Stock
TECX
$312M
| $74.5K | 0.01% |
3,750
+791
| +27% | +$15.7K |
|
390
Erasca
ERAS
$454M
| $72.3K | 0.01% |
56,897
+187
| +0.3% | +$237 |
|
391
Arcturus Therapeutics
ARCT
$453M
| $70.9K | 0.01% |
5,447
+14
| +0.3% | +$182 |
|
392
Maravai LifeSciences
MRVI
$343M
| $69.7K | 0.01% |
28,917
+466
| +2% | +$1.12K |
|
393
Lexicon Pharmaceuticals
LXRX
$407M
| $69K | 0.01% |
72,943
+434
| +0.6% | +$410 |
|
394
Rigel Pharmaceuticals
RIGL
$690M
| $67.2K | 0.01% |
3,590
+57
| +2% | +$1.07K |
|
395
Aquestive Therapeutics
AQST
$463M
| $66K | 0.01% |
19,950
+1,661
| +9% | +$5.5K |
|
396
Absci
ABSI
$350M
| $65.8K | 0.01% |
25,620
+2,582
| +11% | +$6.64K |
|
397
Prothena Corp
PRTA
$445M
| $65.6K | 0.01% |
10,811
+14
| +0.1% | +$85 |
|
398
Terns Pharmaceuticals
TERN
$662M
| $65.4K | 0.01% |
17,541
+504
| +3% | +$1.88K |
|
|
AMRN
399
Amarin Corp
AMRN
$314M
| $65.2K | 0.01% |
4,021
-76,302
| -95% | -$1.24M |
|
400
Prime Medicine
PRME
$556M
| $65.1K | 0.01% |
26,370
+61
| +0.2% | +$151 |
|